Skip to main content
Log in

Prognostic Evaluation of Proliferative Activity and DNA Content in the Phyllodes Tumor of the Breast: Immunohistochemical and Flow Cytometric Study of 118 Cases

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The goal of this study was the prognostic evaluation of histology, mitotic rate, S-phase fraction (SPF) and expression of proliferative antigen Ki67 and p53 protein in phyllodes tumor of the breast. The study was performed in the group of 118 patients with phyllodes tumor treated by surgery from 1952 to 1998. Mitotic rate was assessed on the representative histological specimens. Expressions of Ki67 and p53 were evaluated by immunohistochemistry on a section from the corresponding paraffin blocks which were also used for flow cytometric DNA evaluation. Histologically, 52 tumors were benign (LGM), 24 borderline malignancies (BM) while among 42 malignant tumors, 20 were monomorphous (HGM) and the remaining 22 revealed heterologic elements (HGH). Tumor recurrencies occurred in 17 patients, predominantly during the first three years after surgery, and 13 patients died of the tumor (1 BM, 12 both malignant variants). Multivariate analysis demonstrated mitotic rate, SPF and p53 expression as independent prognostic parameters for the disease-free survival. Histological tumor type and expression of Ki67 influenced independently the overall survival. In conclusion, the histological type of tumor phyllodes forms the basis for the prognosis of clinical outcome, but the indicators of the proliferative activity, especially Ki67 index, are valuable prognostic factors among patients with malignant variant of phyllodes tumor of the breast. Expression of the p53 protein in tumor cells could be also useful when the percentage of cells and intensity of expression are considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Feakins RM, Mulcahy HE, Nickols CD, Wells CA: p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome. Histopathology 35: 162-169, 1999

    Google Scholar 

  2. Layfield LJ, Hart J, Neuwirth H, Bohman R, Trumbull WE, Giuliano AE: Relation between DNA ploidy and the clinical behavior of phyllodes tumor. Cancer 64(7): 1486-1489, 1989

    Google Scholar 

  3. El Naggar AK, Ro JY, McLemore D, Garnsy L: DNA content and proliferative activity of cystosarcoma phyllodes of the breast. Potential prognostic significance. Am J Clin Pathol 93(4): 480-485, 1990

    Google Scholar 

  4. El Naggar AK, Mackay B, Sneige N, Batsakis JG: Stromal neoplasms: a comparative flow cytometric study. J Surg Oncol 44(3): 151-156, 1990

    Google Scholar 

  5. Palko MJ, Wang SE, Shackney SE, Cottington EM, Levitt SB, Hartsock RJ: Flow cytometric S fraction as a predictor of clinical outcome in cystosarcoma phyllodes. Arch Pathol LabMed 114(9): 949-952, 1990

    Google Scholar 

  6. Keelan PA, Myers JL, Wold LE, Katzmann JA, Gibney DJ: Phyllodes tumor: clinicopathologic review of 60 patients and flow cytometric analysis in 30 patients. Hum Pathol 23(9): 1048-1054, 1992

    Google Scholar 

  7. Grimes MM: Cystosarcoma phyllodes of the breast: histologic features, flow cytometric analysis and clinical correlations. Mod Pathol 5(3): 232-239, 1992

    Google Scholar 

  8. Kocova L, Skalova A, Fakan F, Rousarova M: Phyllodes tumor of the breast: Immunohistochemical study of 37 tumours using MIB1 antibody. Path Res Prac 194(1): 97-104, 1998

    Google Scholar 

  9. Witte F, Honig A, Mirecka J, Schauer A: Cystosarcoma phyllodes of the breast: prognostic significance of proliferation and apoptosis associated genes. Anticancer Res 19(4B): 3355-3359, 1999

    Google Scholar 

  10. Umekita Y, Yoshida H: Immunohistochemical study of MIB1 expression in phyllodes tumor and fibroadenoma. Pathol Int 49(9): 807-810, 1999

    Google Scholar 

  11. Kuenen Boumeester V, Henzen-Logmans SC, Timmermans MM, van Staveren LL, van Gal A, Peeterse HJ, Bonnena J, Berns EM: Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast. J Pathol 189(2): 169-175, 1999

    Google Scholar 

  12. Mayzoyer S, Lalle P, Moyret-Lalle C, Marcais C, Schraub S, Frappaz D, Sobol H, Ozturk M: Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene 9(4): 1237-1239, 1994

    Google Scholar 

  13. Shabalova IP, Chemeris GJ, Ermilova VD, Rodionova LM, Pavlikova NA, Syrjanen KJ: Phyllodes tumour: cytologic and histologic presentation of 22 cases and imunohistochemical demonstration of p53. Cytopathology 8(3): 177-187, 1997

    Google Scholar 

  14. Niezabitowski A, Lackowska B, Kruczak A, Rys J, Reinfuss M, Mitus J, Markiewicz D: Evaluation of histology in phyllodes tumor of the breast. A study of 118 cases. Pol J Pathol (in press).

  15. Rosen PP: Breast Pathology. Lippincott-Raven Publishers, Philadelphia-New York, 1997, pp 155-172

    Google Scholar 

  16. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffinembedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335, 1983

    Google Scholar 

  17. Shankey TW, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, Mayall BH, Wheeless LL: Guidelines for implementation of clinical DNA cytometry. Cytometry 14: 472-477, 1993

    Google Scholar 

  18. Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A, Lackowska B, Sokolowski A, Szklarski W: Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70: 150-160, 1999

    Google Scholar 

  19. Remmele W, Stegner HE:Immunohistochemischer Nachweis von Ostrogenreceptoren (ERICA) inMammakarzinomgewebe Vorschlag zur einheitlichen Formulirung des Untresuchungs befundes. Dtsch Arztebl 83: 3362-3364, 1986

    Google Scholar 

  20. Moffat CJC, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO: Phyllodes tumour of the breast: a clinicopathological review of thirty-two cases. Histopathology 27: 207-218, 1995

    Google Scholar 

  21. Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K: The treatment and prognosis of patients with phyllodes tumor of the breast. Cancer 77(5): 910-916, 1996

    Google Scholar 

  22. Holthouse DJ, Smith PA, Naunton-Morgan R, Minchin D: Cystosarcoma phyllodes: The Western Australian experience. Aust NZJ Syrg 69: 635-638, 1999

    Google Scholar 

  23. de Roos WK, Kaye P, Dent DM: Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg 86: 396-399, 1999

    Google Scholar 

  24. Zahner J, Bässler R: The rate of mitosis in cystosarcoma phyllodes (phyllodes tumor WHO) of the breast. An analysis of 47 cases. Arch Gynecol Obstet 246 (3): 153-157, 1989

    Google Scholar 

  25. Murad TM, Hines JR, Beal J, Bauer K: Histopathological and clinical correlations of cystosarcoma phyllodes. Arch Pathol Lab Med 112(7): 752-756, 1988

    Google Scholar 

  26. Millar EKA, Beretov J, Marr P, Sarris M, Clarke RA, Kearsley JH, Lee CS: Malignant phyllodes tumors of the breast display increased stromal p53 protein expression. Histopathology 34: 491-496, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niezabitowski, A., Lackowska, B., Rys, J. et al. Prognostic Evaluation of Proliferative Activity and DNA Content in the Phyllodes Tumor of the Breast: Immunohistochemical and Flow Cytometric Study of 118 Cases. Breast Cancer Res Treat 65, 77–85 (2001). https://doi.org/10.1023/A:1006457304526

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006457304526

Navigation